ASCO Genitourinary Cancers Symposium (Statins again)

[pjoshea13]

"Although limited by sample size, our data showed a trend that statins may mildly enhance the anti-tumor effects of Ab {abiraterone}i in CRPC patients. These results support the findings of Di Lorenzo et al. (2017), and suggest that depletion of de novo cholesterol production may further limit androgen synthesis in concert with CYP17A1 inhibition.

Of course! There is bound to be incremental benefit for some, since we know that de novo cholesterol production is a possible escape strategy. If the results were modest for the group, that doesn't justify ignoring it. PCa has a number of escape pathways open to it. The rational approach is to block them all. As discussed recently - Avodart for backdoor DHT, & so on. Close those windows!

-Patrick

277 Poster Session (Board #N9), Thu, 11:30 AM-1:00 PM and

5:15 PM-6:15 PM

Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi).

Jacob A Gordon, Bernhard J. Eigl, Jennifer A. Locke, Gregory Russell Pond, Cyrus Chehroudi, Daniel Khalaf, Kim N. Chi, Michael E. Cox; Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada; McMaster University, Hamilton, ON, Canada

Background: Epidemiologic studies support an association between statin use and improved prostate cancer specific mortality. Several different biologic mechanisms for such an effect have been proposed, including a potential role in reducing androgen precursor bioavailability. It is hypothesized that statins may therefore improve outcomes specifically in patients treated with the CYP17 inhibitor Abi. Di Lorenzo (2017) recently published an analysis of 187 pts showing a relationship between Abi and improved survival (OS). We report the results of a larger confirma- tory analysis in a separate cohort.

Methods: Disease outcome and statin use were assessed retrospectively in locally advanced or metastatic CRPC patients receiving Abi in British Columbia, Canada. The Kaplan-Meier method was used to estimate survival times, Cox proportional hazards and logistic regression were used to investigate factors potentially prognostic of overall survival and PSA response respectively. A multivariable model was constructed using factors with limited missing data and known biologic rationale. Impact of statins was then assessed adjusting for factors included in the multivariable model.

Results: 301 patients receiving Abi were assessed, of whom 84 (28%) were statin users. Median OS of Abi patients was 11.3 months for non-statin users and 16.2 months for statin users (hazard ratio = 0.79, 95% CI = 0.61-1.03, p = 0.079). Effect of statin use remained borderline after adjusting (n = 279, hazard ratio = 0.78, 95% CI = 0.59-1.04, p = 0.087) for age, prior prostatectomy, radiation, Docetaxel, time from diagnosis, neutrophils-lymphocyte ratio and presence of metastases. Forty-eight percent of statin users and 37% of non-statin users had a PSA response (multivariable odds ratio = 1.59, 95% CI = 0.91-2.78, p = 0.11).

Conclusions: Although limited by sample size, our data showed a trend that statins may mildly enhance the anti-tumor effects of Abi in CRPC patients. These results support the findings of Di Lorenzo et al. (2017), and suggest that depletion of de novo cholesterol production may further limit androgen synthesis in concert with CYP17A1 inhibition. Further studies are warranted.

[BigRich]

After reading your earlier posts, Last year, I went on the statin you take.

The highest form of flattery is to imitate.

Rich